In short, I would say that biomarkers reflecting amyloid and tau pathology have been developed a lot. There are phospho-tau 217, 131, 181, and amyloid PET and tau PET and MTBR-tau243. So we have a lot of biomarkers which can track the amyloid and tau progression. But according to the ATN criteria, the N category, the neurodegeneration, biomarkers reflecting N are limited. Imaging approaches such as FDG PET and MRI, they are expensive and they’re not always practical for longitudinal or large-scale studies...
In short, I would say that biomarkers reflecting amyloid and tau pathology have been developed a lot. There are phospho-tau 217, 131, 181, and amyloid PET and tau PET and MTBR-tau243. So we have a lot of biomarkers which can track the amyloid and tau progression. But according to the ATN criteria, the N category, the neurodegeneration, biomarkers reflecting N are limited. Imaging approaches such as FDG PET and MRI, they are expensive and they’re not always practical for longitudinal or large-scale studies. And there’s just one biomarker in the field, which is NFL, but it is a generic marker and it is not AD specific and it is also influenced by the peripheral sources. So that’s why there’s a need to find an AD-specific neurodegenerative biomarker which can track neurodegeneration specifically.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
